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ABSTRACT.
Purpose: Compare (a) nonmitomycin C (MMC) trabeculectomy and 1.5%
dexamethasone nanoparticle (DexNP) eye drops postoperatively with (b)
trabeculectomy with MMC and Maxidex eye drops postoperatively.
Methods: Randomized prospective single masked clinical trial with 20 patients
with primary open-angle glaucoma undergoing primary trabeculectomy. The
study group consisted of 10 patients without MMC intraoperatively and
postoperative DexNP eye drops, and the control group consisted of 10 patients
treated with MMC intraoperatively and postoperative Maxidex. The drops
were tapered out over 8 weeks. The main outcome measures were as follows:
rates of complete success, that is intraocular pressure (IOP) within target
pressures at different time-points without IOP-lowering medication, or reoper-
ation. Secondary outcome measures included the following: relative success rate
(with IOP-lowering medications), number of glaucoma medications and reop-
erations. Patients were followed for 36 months.
Results: Both groups showed similar postoperative course and IOP reduction.
Intraocular pressures (IOPs) in the DexNP group and in the control group were
25.6 and 24.4 mmHg, respectively, at baseline. Intraocular pressures (IOPs)
were reduced to 13.2 and 14.5 mmHg at 12 months, 11.7 and 12.6 mmHg at
24 months and 11.7 and 12.1 mmHg at 36 months, respectively. There were no
statistically significant differences between the groups in absolute (p = 0.36) or
relative (p = 1.0) success rates, number of medications (p = 0.71) or reopera-
tions (p = 1.0) between the groups at any time-point.
Conclusions: DexNP eye drops are effective postoperative treatment following
trabeculectomy. The potent anti-inflammatory and antifibrotic effect of DexNP
may offer an alternative to mitomycin C in glaucoma surgery.
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Introduction
Trabeculectomy is the most commonly
used method of filtration surgery per-
formed to lower IOP in glaucoma
(EGS 2014), and it is still considered
by many to be the gold standard in
glaucoma surgery (Conlon et al. 2017).
The procedure, in which an alternative
outflow pathway for aqueous humour
is created, sparks a healing reaction in
which the body tries to close the
pathway through inflammation and
scarring, potentially causing the sur-
gery to fail. To counteract this reac-
tion, mitomycin C (MMC) is
frequently used intraoperatively. Mito-
mycin C is a naturally occurring com-
pound with an antiproliferative
activity. It acts as an alkylating agent
after enzyme activation, resulting in
DNA cross-linking (Seibold et al.
2012). Thus, MMC is a potent antifi-
brotic agent that reduces scar tissue
formation and its use in trabeculec-
tomy results in higher success rates
(Wilkins et al. 2005; Cabourne et al.
2015).
However, the rate of serious postop-
erative complications may increase,
and the use of MMC in filtering
surgery is associated with an increased
risk of hypotony maculopathy, thin-
walled blebs, blebitis, endophthalmitis,
and corneal epithelial toxicity (Hollo
2012). In addition to MMC, and to
further diminish the healing reaction
and scar tissue formation following
filtration surgery, the patients receive
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topical steroids postoperatively to treat
postsurgical inflammation. The most
commonly used steroid is dexametha-
sone (Maxidex).
Cyclodextrin nanoparticles have
recently been shown to be an effective
drug delivery technology to transport
lipophilic drugs into the eye. Cyclodex-
trins are oligosaccharides with a hydro-
philic outer surface and a lipophilic
central cavity. Therefore, they can trans-
port lipophilic drugs in their cavity and
thus enhance drug delivery through the
tough barriers of the eye surface into the
eye (Loftsson et al. 2008).
The steroid dexamethasone has been
shown to be a suitable candidate for
this nanoparticle technology (Loftsson
et al. 2007; Sigurdsson et al. 2007;
Loftsson & Stefansson 2007). After
instillation of one drop of 1.5% dex-
amethasone cyclodextrin nanoparticle
suspension (DexNP), dexamethasone
can be measured in the tear film for
at least 6 hr after being instilled in the
eye (Johannesson et al. 2014), enabling
higher absorption into the eye with
potentially enhanced treatment effect.
DexNP has been used as topical treat-
ment in humans in both diabetic mac-
ular oedema and uveitis with promising
results with significant decrease of
macular oedema and increase in visual
acuity. (Tanito et al. 2011; Krag &
Hessellund 2014; Ohira et al. 2015;
Shulman et al. 2015) Furthermore, in a
study by Saari et al. (2006), postoper-
ative inflammation after cataract sur-
gery was shown to be significantly less
with 0.7% dexamethasone in cyclodex-
trin aqueous solution given once daily
than with commercially available 0.1%
dexamethasone sodium phosphate
three times daily.
All these studies demonstrate
DexNP as being potent and effective
for treatment of intraocular inflamma-
tion. Corticosteroids are also known to
have antifibrotic effect (Armstrong
et al. 2019). Therefore, we hypothesize
that postoperative treatment with
DexNP after trabeculectomy will sup-
press inflammation and fibrosis so
effectively that intraoperative use of
MMC is not necessary.
Materials and methods
This was a prospective, randomized,
single masked, single-centre study per-
formed at the Eye Clinic, Department
of Ophthalmology, University of
Iceland. The study was performed in
accordance with the Declaration of
Helsinki and approved by the Icelandic
Medicines Agency and the Icelandic
Biomedical Ethics board. The study
was registered at the European Clinical
Trials Database (EudraCT no: 2013-
001093-16). Patients scheduled for pri-
mary trabeculectomy between Septem-
ber 2013 and January 2014 were asked
to participate. Inclusion criteria
included the following: patients with
the diagnosis of primary open-angle
glaucoma (POAG), age >18 years and
ability to sign informed consent form.
Exclusion criteria included the follow-
ing: any active ocular disease or infec-
tion, allergy to the study medication,
pregnant and breastfeeding women,
those unable to understand informed
consent and those who had partici-
pated in any clinical study during the
previous 6 months.
The study drug, 1.5% dexametha-
sone c-cyclodextrin nanoparticle
(DexNP) eye drops were manufactured
at Fresenius Kabi in Austria in 10-mL
glass vials. The eye drops which contain
a preservative were transferred to eye
drop bottles with drop counter at the
hospital pharmacy production unit at
Landspitali – The National University
Hospital of Iceland where the eye drops
were dispensed to the patients. The eye
drops were self-administered by the
patients. Patients did receive training
from a study nurse on the use of the eye
drops. They also received written
instruction on how to self-administer
the eye drops and were instructed to
shake the eye drop bottle before use as
the formulation is a suspension.
Prior to the inclusion, five subjects
took part in an open-label pilot study
performed as a safety measure to
evaluate the risk for serious adverse
effects in the first weeks following
surgery. Those subjects were allocated
to the trabeculectomy without MMC
but with DexNP drops four times
daily. No serious adverse effects
occurred in those five patients between
surgery and when the randomized
study was started. According to study
protocol, the results of the first five
subjects were not included in the
analysis as they were neither random-
ized nor masked.
Subjects included in the second part
of the study were randomized to either:
(a), the study group, with trabeculec-
tomy without MMC and postoperative
treatment with DexNP drops four
times daily or (b), the control group,
with trabeculectomy with intraopera-
tive application of MMC (0.3 mg/ml
for 2 min) and postoperative treatment
with commercially available Maxidex
drops six times daily. The postopera-
tive eye drops were tapered down
during eight weeks (w) as follows:
subjects in the non-MMC arm used
DexNP drops four times daily for four
weeks, then three times daily for two
weeks, then two times daily for 1 week
and finally once daily for 1 week.
Subjects in the MMC arm used Max-
idex eye drops six times daily for four
weeks, then four times daily for two
weeks and finally two times daily for
2 weeks.
All surgeries were performed by one
surgeon (MSG). After topical and sub-
tenon anaesthesia, a fornix-based con-
junctival flap was made superiorly.
Sponges soaked in either 0.3 mg/ml
MMC or balanced salt solution (BSS),
depending on which group the subject
Fig. 1. Flow chart. Mors = deceased subject, m = month, y = year.
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was randomized to, were instilled under
the conjunctiva for two minutes. Then,
the subconjunctival space was irrigated
thoroughly withBSS.A partial thickness
sclera flap was created and a fistula was
madeunderneath theflapand iridectomy
was performed. The scleral flap was then
sutured with four 10.0 nylon single
sutures. Finally, the conjunctiva was
closed with a running 8/0 vicryl suture.
The surgeonand the subjectweremasked
to whether the subject got sponges with
MMCor BSS. The surgeon continued to
be masked throughout the trial but the
subjects received unmasked bottles with
eitherMaxidex or DexNP. Thus, it was
possible for the subjects to know which
group they belonged. Intraocular pres-
sure measurement was performed once
with Goldmann Applanation
Tonometry at every postoperative con-
trol by the surgeon.
The main outcome measure was IOP
change after trabeculectomy and the rate
of complete success defined as IOP
≥6 mmHg and ≤18 mmHg without
IOP-lowering medication or an addi-
tional IOP-lowering operation. Accord-
ing to theWorldGlaucomaAssociation’s
guidelines on designing glaucoma trials,
the definition of IOP success ought to
include an upper and lower limit, include
more than one upper limit or a combina-
tion of an upper limit and a percentage
reduction (Shaarawy 2009). Thus, the
results in this study are reported with a
lower limit and several upper limits.
Secondaryoutcomemeasures included
the following: relative success defined as
IOP ≥6 mmHg and ≤18 mmHg with or
without additional IOP-loweringmedica-
tion. Secondary outcome measures
includedincidenceofmedicalandsurgical
interventions (needofpostoperativemed-
ications, needling, laser suture lysis and
bleb needling) and safety.
Treatment could be stopped in cases
suggesting drug intolerance.
End-point of the study was the
occurrence of reoperation due to fail-
ure of the previous glaucoma opera-
tion. The decision of performing
reoperation was made by the surgeon
when target IOP was not fulfilled
despite suture lysis and/or IOP-lower-
ing topical medication. The patients
were followed for 36 months.
Statistical analysis
Summary statistics are presented with
means and range. The Wilcox signed-
rank test was used in paired samples and
Mann–Whitney U-test for nonpaired
samples for IOPmeasures. A generalized
mixed-effect model with fixed effect for
timeafteroperationandarandomsubject
effectwas used.Anothermodelwith fixed
effect for treatment and random subject
effect for patients was fitted against the
number of medications used. A Poisson
likelihood was assumed in these two
models. A two-sample test for equality
was used to test proportions. A mixed-
effectmodelwithfixedeffect for timeafter
operation, treatment and interaction
between time and treatment, and random
subject effect was fitted to test the associ-
ation with IOP. A general estimating
equation was used to test the association
of treatment with rate of success. Statis-
tical significance was set at p = 0.05.
Results
The study included a total of 20 patients
with POAG undergoing primary tra-
beculectomy because of poorly con-
trolled IOP and/or intolerance to
topical eye drops. All patients had glau-
comatous optic nerve head damage and
corresponding visual field defects. None
of the patients in either group had
previously undergone filtering surgery.
One patient in the DexNP group had
performed argon laser trabeculoplasty
eight months prior to surgery. The study
group included 10 subjects treated with
DexNP without MMC, and the control
group included 10 subjects treated with
MMC and Maxidex (Fig. 1). Three
patients in the DexNP arm died during
the study time, two before the 2-year
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0.20 (0.05–0.7) 0.2 (0.05–1.0)
Table 2. Results of IOP, number of glaucoma medications and reoperations in the two treatment arms. IOP is with or without glaucoma medication
and data are given as mean IOP (range) and number of subjects at each time point. Medicines refers to number of medications at each time point and
data are given as mean (range). Re-operation shows the number of subjects that had gone through re-operation/total subjects.
Pre op 3 months p* 6 months p* 12 months p* 24 months p* 36 months p*
IOP (mm Hg)
DexNP 25.6 (16-38) 10 14.6 (10-30) 9 0.012 14.9 (10-30) 9 0.021 13.2 (10-18) 8 0.014 11.7 (7-16) 7 0.022 11.7 (9-17) 6 0.035
Maxidex 24.4 (16-42) 10 12.7 (8-18) 10 0.006 13.1 (9-17) 10 0.002 14.5 (9-28) 10 0.006 12.6 (8-25) 8 0.025 12.1 (9-16) 7 0.016
p 0.57 0.68 0.65 0.929 0.769 0.768
Medicine
DexNP 2.7 (1-4) 0 (0-0) NA** 0.2 (0-2) 0.001 0.5 (0-2) 0.002 0.7 (0-2) 0.008 0.8 (0-2) 0.018
Maxidex 2.6 (0-4) 0 (0-0) NA** 0.2 (0-1) 0.001 0.6 (0-4) 0.001 0.2 (0-2) 0.002 0.7 (0-2) 0.017
p 0.929 1 0.949 0.888 0.21 0.807
Reoperation
DexNP 1/10 1/10 2/10 1/8 1/7
Maxidex 0/10 0/10 0/10 2/10 3/10
p 0.864
DexNP = 1.5% dexamethasone cyclodextrin nanoparticles suspension, IOP = intraocular pressure, Maxidex = commercially available dexametha-




control. The demographics of the study
population can be seen in Table 1.
The IOP was reduced in both treat-
ment arms at all time–points, and there
was no statistically significant differ-
ence between the treatment arms at any
time-point (Table 2, Fig. 2). The por-
tion of subjects reaching absolute and
relative success is shown in Table 3.
Figure 2A–C shows the individual
relationships between pre- and postop-
erative IOP and whether the IOP
reduction was more than 25% as com-
pared with the preoperative IOP level.
There was no difference between the
treatment arms in terms of number of
glaucoma medications or surgical fail-
ures, in which case the patients needed
to undergo additional surgical inter-
vention, that is shunt operation with an
Ahmed valve (Table 2). Suture lysis
was performed in eight subjects in the
DexNP arm and in nine subjects in the
MMC/Maxidex arm. No needlings or
5-FU injections were performed post-
operatively on subjects in either group.
Baseline visual acuity is presented in
Table 1. Visual acuity was significantly
decreased compared to baseline at
three, six and 24 months in the DexNP
group by 0.05  0.04, 0.05  0.06 and
0.06  0.06 logMAR, respectively. For
the MMC/Maxidex group, visual acu-
ity was significantly decreased at 3, 6
and 10 months by 0.05  0.04,
0.04  0.04 and 0.04  0.04 logMAR,
respectively. There was no significant
difference in visual acuity change
between the groups at any time-point.
Discussion
The results of this prospective, random-
ized study show no difference between
trabeculectomy performed with adju-
vant MMC and regular topical dexam-
ethasone (Maxidex) postoperatively as
compared with trabeculectomy without
MMC and with topical DexNP postop-
eratively. This indicates that the anti-
inflammatory and antifibrotic effect of
DexNP is noninferior compared with
the antifibrotic effect of MMC in tra-
beculectomy.
Antimetabolites such as MMC and
5-FU are widely used to prevent scar-
ring of the bleb in trabeculectomy.
Studies have shown MMC to have
superior antifibrotic effects compared
with 5-FU (Cabourne et al. 2015), and
thus, MMC has become a standard
procedure in trabeculectomy. In a
Fig. 2. Scatterplot showing preoperative intraocular pressure (IOP) plotted against postoperative
IOP at (A) 12 months, (B) 24 months and (C) 36 months in the two treatment arms. All symbols
below the black line represent eyes where IOP was lower postoperatively than preoperatively. The
dashed line represents eyes with IOP reduction more than 25%.
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Cochrane review of the use of MMC in
glaucoma surgery, Wilkins et al. (2005)
concluded that intraoperative MMC
reduces the risk of surgical failure in
primary trabeculectomy, and com-
pared with placebo, MMC reduces the
mean IOP of all reviewed participants
at 12 months.
The disadvantage of using MMC in
filtrating surgery is the risk of compli-
cations associated with antimetabolites.
Reports on vision-threatening compli-
cations such as scleral melting (Cou-
tinho et al. 2017), avascular and
atrophic conjunctiva (Siggel & Dietlein
2018), wound leaks (Membrey et al.
2000; Soltau et al. 2000) andbleb-related
infections (Luebke et al. 2019), hypot-
ony (Suner et al. 1997) and cataract
formation (Wilkins et al. 2005) have
been linked to the use ofMMC. The risk
of complications is greater with longer
duration of intraoperative MMC expo-
sure and higher concentrations ofMMC
(Robin et al. 1997; Kim et al. 1998;
Wilkins et al. 2005). Thus, it is important
to limit duration and exposure toMMC
in order to minimize the risk of compli-
cations, and in this study, MMC appli-
cations were within the limits proposed
by The Moorfields Safer Surgery rec-
ommendations (Dhingra & Khaw
2009).
However, it is important to point out
that these feared complications are rare
(Luebke et al. 2019) and that surgeons
have developed techniques to reduce the
incidence of these complications (Wilk-
ins et al. 2005). Furthermore, a limita-
tion ofmany studies of filtration surgery
is too short follow-up time as many of
the potential MMC complications are
late-onset (Soltau et al. 2000; Wilkins
et al. 2005). Luebke et al. (2019) report
results from more than 1800 trabeculec-
tomies in which they identifiedMMC as
a significant risk factor for bleb-related
infection. However, and in contrast, in
another recent retrospective review of
trabeculectomy-related complications,
which spans a period of 25 years, the
authors could not see an increase of
complications that could be linked to
the use of MMC (Olayanju et al. 2015).
In this present prospective study,we had
a follow-up period of three years and did
not see any serious complications in
either arm of the study.
Harju et al. showed in a randomized
controlled trial on deep sclerectomy
with either MMC or not, that although
the group with MMC had higher suc-
cess rates, a statistical difference was
not reached at the end of follow-up.
Success with low IOP in the non-MMC
group was maintained with higher
frequencies of postoperative interven-
tions of goniopunctures and needling
procedures (Harju et al. 2018). No
difference in postoperative suture lysis
was seen in that study.
The nanotechnology-based drug
delivery technology used in DexNP has
been investigated in several human clin-
ical trials with good results. In two
studies on subjects with diabetic macu-
lar oedema, treatment with topical
DexNP significantly reduced central
macular thickness and increased visual
acuity (Tanito et al. 2011; Ohira et al.
2015). Furthermore, topical DexNP has
been used to treat patients with inter-
mediate uveitis and cystoid macular
oedema with significantly improved
clinical status (Krag & Hessellund
2014; Shulman et al. 2015). Thus,
DexNP has been proven effective to
treat conditions deep in the eye, which is
unusual for topical eye drops due to the
immense barriers to drug penetrance in
the eye (Loftsson et al. 2008). Encour-
aged by these results, the current study
was undertakenwith the hypothesis that
the enhanced uptake of dexamethasone
would be comparable to MMC.
Although small, the study confirmed
the hypothesis that trabeculectomy
without MMC and with DexNP was
noninferior to trabeculectomy with
MMC and conventional dexametha-
sone postoperative treatment. This indi-
cates that the strong penetrance of
DexNP might be an alternative to
MMC in filtration surgery.
Table 3. (a) Portion of subjects reaching absolute success (IOP ≥ 6 mmHg and ≤18 mm Hg)
without IOP-lowering medications. (b) Portion of subjects reaching relative success
(IOP ≥ 6 mmHg and ≤18 mmHg) with or without IOP-lowering medications.
3 months 6 months 12 months 24 months 36 months
(a)
DexNP 80% (8/10) 70% (7/10) 50% (5/10) 37.5% (3/8) 28.6% (2/7)
Maxidex 100% (10/10) 80% (8/10) 70% (7/10) 60% (6/10) 40% (4/10)
All 90% (18/20) 75% (15/20) 60% (12/20) 50% (9/18) 35.3% (6/17)
p 0.46 1 0.65 0.64 1
(b)
DexNP 80% (8/10) 80% (8/10) 80% (8/10) 87.5% (7/8) 85.7% (6/7)
Maxidex 100% (10/10) 100% (10/10) 80% (8/10) 70% (7/10) 70% (7/10)
All 90% (18/20) 90% (18/20) 80% (16/20) 77.8% (14/18) 76.5% (13/17)
p 0.46 0.46 1 0.75 0.86
Data are given as % success and as no. of subjects out of total no. of subjects.
Fig. 3. Boxplot with absolute IOP values at baseline and at postoperative controls. Number of
subjects is indicated above the x-axis. Boxes show 25% percentile and 75% percentile with a
horizontal line representing the median value.
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There are limitations in this study
that need to be acknowledged. Firstly,
the study is a pilot study with a small
sample size. Thus, it cannot be
excluded that a larger sample might
have produced a significant difference
between the treatment arms. Secondly,
the surgeon was masked to whether the
patients received MMC or not intra-
operatively, but the patients were not
masked to whether they received
DexNP or Maxidex during their ini-
tial postoperative period which could
theoretically have affected the subjects’
compliance. Ideally, the drugs would
have been repackaged into similar bot-
tles but that was not possible in this
study. Finally, it is notable that several
subjects needed to undergo reoperation
with shunt and thus were classified as
failures. However, these were more
frequent in the MMC/Maxidex arm
and can therefore not be due to the
absence of MMC.
In conclusion, this study showed
that there was no statistical difference
between using postoperative treatment
with DexNP eye drops in trabeculec-
tomies without MMC compared with
postoperative treatment using conven-
tional steroid drops (Maxidex) in
trabeculectomies with MMC. This sug-
gests that the use of DexNP, with its
large anti-inflammatory and antifi-
brotic effect, could reduce or even in
some cases replace the use of MMC
perioperatively.
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